Drug Trial Radar · NCT00364858
Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease
Last checked: Nov 19, 2026Latest source record: Apr 3, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
95
Actual
Start
Dec 2001
Primary completion
Not stated
Study completion Feb 2007
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Aug 16, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized trial to compare the safety and efficacy of two dosing frequencies of Cerezyme® in patients with Gaucher disease who are currently being treated with Cerezyme®. Approximately 90 patients will be randomized in a 2:1 (q4 : q2) ratio to one of two treatment arms at up to 26 study centers worldwide. Patients will continue to receive the same total 4-week dose that they were receiving prior to study enrollment, however, they will be randomized to receive either their total 4-week dose in two infusions, one infusion every 2 weeks or their total 4-week dose in one infusion every 4 weeks. The randomization scheme will ensure a 2:1 balance between the every 4-week versus every 2-week infusion groups, respectively.
Conditions
- Gaucher Disease, Type 1
- Cerebroside Lipidosis Syndrome
- Glucocerebrosidase Deficiency Disease
- Glucosylceramide Beta-Glucosidase Deficiency Disease
- Gaucher Disease, Non-Neuronopathic Form
Interventions
CerezymeDrug
Cerezyme doses of 20-60U/kg every 2 weeks (Q2 Arm) or 40-120 U/kg every 4 weeks (Q4 Arm).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Clinical Success at Month 24/DiscontinuationTime frame: Month 24 (or at time of discontinuation)
Locations
26 sites in 7 countries. Site status is shown where the registry gives one.
Children's National Medical Center
Washington D.C., District of Columbia
University Research Foundation for Lysosomal Storage Disease, Inc.
Coral Springs, Florida
Emory University
Atlanta, Georgia
Children's Memorial Hospital
Chicago, Illinois
Midwest Cancer Research Group, Inc.
Skokie, Illinois
Massachusetts General Hospital
Boston, Massachusetts
Institute for Genetics Medicine Saint Peter's University Hospital
New Brunswick, New Jersey
Holy Name Hospital
Teaneck, New Jersey
Hemophilia Center of Western New York
Buffalo, New York
New York Oncology/Hematology PC
Latham, New York
New York University
New York, New York
Mt. Sinai Medical Center
New York, New York
Duke University Medical Center
Durham, North Carolina
Children's Hospital Research Foundation
Cincinnati, Ohio
Oregon Health & Science University
Portland, Oregon
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania
University of Utah
Salt Lake City, Utah
Estadual de Hematologia Arthur de Siqueira Cavalcanti (HEMORIO)
Rio de Janeiro, Brazil
Mount Sinai Hospital
Toronto, Ontario, Canada
Istituto Giannina Gaslini
Genova, Italy
Universita degli Studi di Napoli "Federico II"
Naples, Italy
Istituto per l'Infanzia Burlo-Garofolo
Trieste, Italy
Instytut Pomnik Centrum Zdrowia Dzeicka
Warsaw, Poland
Hospital Vall d´Hebrón
Barcelona, Spain
Royal Free Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.